TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 58,702 shares. The stock had previously closed at $0.13.
TC Biopharm Stock Down 9.8 %
The firm's fifty day moving average is $0.14 and its 200-day moving average is $0.15.
Get TC Biopharm alerts:Institutional Trading of TC Biopharm
An institutional investor recently bought a new position in TC Biopharm stock. Nantahala Capital Management LLC bought a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,294 shares of the company's stock, valued at approximately $117,000.
TC Biopharm Company Profile
(Get Rating)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
See Also
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don't Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
納斯達克(TCBPW-GET Rating)股價週五午盤下跌9.8%。該股交易價格低至0.11美元,最後報0.11美元。午盤交易中,約有1,500股易手,較58,702股的日均成交量下降了97%。該股此前收盤價為0.13美元。
TC生物製藥類股下跌9.8%
該公司的50日移動均線切入位為0.14美元,200日移動均線切入位為0.15美元。
到達TC生物醫藥警報:TC生物藥品的制度性交易
一家機構投資者最近買入了TC生物製藥股票的新頭寸。根據南原資本管理有限責任公司提交給美國證券交易委員會(美國證券交易委員會)的最新表格13F檔案,該公司在第一季度購買了TC生物製藥(控股)有限公司(TCBPW-GET Rating)的新股票頭寸。該機構投資者購買了235,294股該公司股票,價值約11.7萬美元。
TC生物製藥公司簡介
(獲取評級)
TC生物製藥(控股)公司是一家臨床階段的生物製藥公司,專注於開發基於其同種異體伽馬三角洲T細胞平臺的免疫治療產品。它的產品線包括用於治療急性髓系白血病的未經修飾的細胞療法OmnImmune;用於治療新冠肺炎的未經修飾的細胞療法免疫斯蒂姆;用於治療消化道癌症的TCB009;以及用於同種異體共刺激GD-T CAR的臨床前候選藥物TCB005/TCB006,它們將針對各種實體腫瘤類型上表達的抗原。
另請參閱
- 免費獲取StockNews.com關於TC生物藥物的研究報告(TCBPW)
- 這項具有巨大增長前景的小型技術正在接近買入點
- 不要追逐聯盟快遞更高,等待回調
- 防禦性科技投資組合的3只股票
- 從這3頭現金母牛身上榨取分紅
- 歐洲加息,美聯儲應該效仿嗎?
接受《TC生物醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對TC生物製藥和相關公司評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧